The Current Procedural Terminology (CPT) Category III code for the Unfold AI prostate cancer mapping platform can be utilized by radiologists starting in July 2024.
The 2024 Current Procedural Terminology (CPT) codes from the American Medical Association (AMA) will include a new category III CPT code for the use of Unfold AI, an artificial intelligence (AI)-enabled mapping platform for prostate cancer imaging.
Unfold AI is reportedly the first AI-powered prostate cancer modality to receive a category III CPT code, according to Avenda Health, the manufacturer of Unfold AI.1
Avenda Health said the X237T CPT code, which goes into effect in July 2024, can be utilized for “Non-invasive prostate cancer estimation map, derived from augmentative analysis of image-guided fusion biopsy and pathology, including visualization of margin volume and location, with margin determination and physician interpretation and report.”
"The new CPT code solidifies our position as a frontrunner in revolutionizing cancer care and our commitment to making our technology accessible to all patients,” noted Brittany Berry-Pusey, Ph.D., the COO and co-founder of Avenda Health.
In a retrospective study published earlier this year, researchers found that AI model margins with Unfold AI demonstrated a 96.9 percent sensitivity for diagnosing clinically significant prostate cancer (csPCa) in comparison to 37.4 percent for regions of interest (ROI) on conventional magnetic resonance imaging (MRI).2
References
1. Avenda Health. Avenda Health’s revolutionary AI mapping tool for prostate cancer achieves landmark category III CPT code designation. Cision PR Newswire. Available at: https://www.prnewswire.com/news-releases/avenda-healths-revolutionary-ai-mapping-tool-for-prostate-cancer-achieves-landmark-category-iii-cpt-code-designation-301973699.html . Published November 1, 2023. Accessed November 1, 2023.
2. Hall J. Study says AI mapping more effective than MRI for assessing extent of prostate cancer. Diagnostic Imaging. Available at: https://www.diagnosticimaging.com/view/study-says-ai-mapping-more-effective-than-mri-for-assessing-extent-of-prostate-cancer . Published June 15, 2023. Accessed November 1, 2023.
ACR Collaborative Model Achieves 20 Percent Improvement in PI-QUAL Scores for Prostate MRI
May 9th 2024Using a learning network model to discuss challenges and share insights among radiology departments from five different organizations, researchers noted that 87 percent of audited prostate MRI exams had PI-QUAL scores > 4 at the conclusion of the collaborative program.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.